Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2014 (2014), Article ID 379431, 9 pages
http://dx.doi.org/10.1155/2014/379431
Research Article

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011

1Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand
2New Zealand Brain Research Institute, 66 Stewart Street, Christchurch 8011, New Zealand
3Department of Neurology, Canterbury District Health Board, Private Bag 4710, Christchurch 8140, New Zealand

Received 18 December 2013; Revised 26 January 2014; Accepted 27 January 2014; Published 4 March 2014

Academic Editor: Ted Dawson

Copyright © 2014 T. L. Pitcher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Wang, L. Dwyer-Lindgren, K. T. Lofgren et al., “Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9859, pp. 2071–2094, 2012. View at Publisher · View at Google Scholar
  2. Pharmac, Agents for Parkinsonism and Related Disorders, Pharmac Schedule Online, Wellington, New Zealand, 2013, http://www.pharmac.govt.nz/patients/PharmaceuticalSchedule.
  3. WHO Collaborating Centre for Drug Statistics Methodology, The Anatomical and Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD), Norwegian Institute of Public Health, 2012.
  4. Statistics New Zealand, National Population Estimates: June 2011 Quarter, Statistics New Zealand, Wellington, New Zealand, 2011, http://www.stats.govt.nz/browse_for_stats/population/estimates_and_projections.
  5. F. Andersohn and E. Garbe, “Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists,” Movement Disorders, vol. 24, no. 1, pp. 129–133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Shaunak, A. Wilkins, J. B. Pilling, and D. J. Dick, “Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 1, pp. 79–81, 1999. View at Google Scholar · View at Scopus
  7. R. S. Schwab, A. C. England Jr., D. C. Poskanzer, and R. R. Young, “Amantadine in the treatment of Parkinson's disease,” Journal of the American Medical Association, vol. 208, no. 7, pp. 1168–1170, 1969. View at Google Scholar · View at Scopus
  8. N. J. Crosby, K. H. Deane, and C. E. Clarke, “Amantadine for dyskinesia in Parkinson's disease,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003467, 2003. View at Google Scholar · View at Scopus
  9. Y. Ben-Shlomo, A. Churchyard, J. Head et al., “Investigation by Parkinson's disease research group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry,” British Medical Journal, vol. 316, no. 7139, pp. 1191–1196, 1998. View at Google Scholar · View at Scopus
  10. S. Kaakkola, “Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease,” Drugs, vol. 59, no. 6, pp. 1233–1250, 2000. View at Google Scholar · View at Scopus
  11. A. J. Lees, “Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom,” British Medical Journal, vol. 311, no. 7020, pp. 1602–1607, 1995. View at Google Scholar · View at Scopus
  12. C. W. Olanow, “Tolcapone and hepatotoxic effects. Tasmar Advisory Panel,” Archives of Neurology, vol. 57, no. 2, pp. 263–267, 2000. View at Publisher · View at Google Scholar
  13. H. Y. Meltzer, “Update on typical and atypical antipsychotic drugs,” Annual Review of Medicine, vol. 64, pp. 393–406, 2013. View at Google Scholar
  14. R. Katzenschlager, C. Sampaio, J. Costa, and A. Lees, “Anticholinergics for symptomatic management of Parkinson's disease,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003735, 2003. View at Google Scholar · View at Scopus
  15. M. Pollock and R. W. Hornabrook, “The prevalence, natural history and dementia of parkinson's disease,” Brain, vol. 89, no. 3, pp. 429–448, 1966. View at Publisher · View at Google Scholar · View at Scopus
  16. T. H. Caradoc-Davies, M. Weatherall, G. S. Dixon, G. Caradoc-Davies, and P. Hantz, “Is the prevalence of Parkinson's disease in New Zealand really changing?” Acta Neurologica Scandinavica, vol. 86, no. 1, pp. 40–44, 1992. View at Google Scholar · View at Scopus
  17. S. L. Kowal, T. M. Dall, R. Chakrabarti, M. V. Storm, and A. Jain, “The current and projected economic burden of Parkinson's disease in the United States,” Movement Disorders, vol. 28, pp. 311–318, 2013. View at Google Scholar
  18. Statistics New Zealand, Demographic Trends: 2012, Statistics New Zealand, Wellington, New Zealand, 2013, http://www.stats.govt.nz/browse_for_stats/population/estimates_and_projections/dem-trends-landing-page.aspx.
  19. J. de Pedro-Cuesta, I. J. Petersen, L. Stawiarz et al., “High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? Europarkinson Preparatory Activity Research Group,” Acta Neurologica Scandinavica, vol. 91, no. 2, pp. 79–88, 1995. View at Google Scholar · View at Scopus
  20. J. de Pedro-Cuesta, L. Wermuth, V. Abraira, and L. Stawiarz, “Levodopa use in Denmark: high levels in Greenland and the Faroe Islands. Europarkinson Preparatory Activity Research Group,” Acta Neurologica Scandinavica, vol. 91, no. 2, pp. 89–97, 1995. View at Google Scholar · View at Scopus
  21. E. A. Osinaga, L. C. A. Inchaurregui, I. E. Ikobaltzeta, N. B. Alonso, and J. G. del Pozo, “A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992–2004),” Parkinsonism and Related Disorders, vol. 13, no. 8, pp. 500–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. M. Rosa, J. J. Ferreira, M. Coelho, R. Freire, and C. Sampaio, “Prescribing patterns of antiparkinsonian agents in Europe,” Movement Disorders, vol. 25, no. 8, pp. 1053–1060, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. Health Funds Association of New Zealand, “Fact File—Health Insurance in New Zealand,” May 2013, http://www.healthfunds.org.nz/pdf/HFANZ_Fact_File_April_2013.pdf.